Inclisiran

(Leqvio®)

Inclisiran

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous; 284 mg/1.5 mL)
Drug ClassSmall interfering RNAs (siRNAs)
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Product Monograph / Prescribing Information

Document TitleYearSource
Leqvio (inclisiran) Prescribing Information.2023Novartis Pharmaceuticals Corporation, East Hanover, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials.2023Frontiers in Pharmacology
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis.2022Cardiovascular Diabetology
Clinical and pharmacoeconomic combined report.2022CADTH
Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol. 2022Journal of the American Heart Association
The promising novel therapies for familial hypercholesterolemia.2022Journal of Clinical Laboratory Analysis
Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis.2022Current Medical Research and Opinion
Assessment report: Leqvio.2021EMA
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia.2021NICE
Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value.2021ICER
Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis.2021Journal of the American College of Cardiology
A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with inclisiran.2020The American Journal of Cardiology
Meta-analysis of inclisiran for the treatment of hypercholesterolemia.2020The American Journal of Cardiology

Clinical Practice Guidelines